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Abstract
Introduction This study investigates the treatment and
survival of young versus elderly potentially curable gastric
cancer patients in the Netherlands.
Patients and methods All noncardia gastric cancer patients
with potentially curable gastric cancer according to stage
(cTx–3, cNx–3, and cMx–0) diagnosed between 1989 and
2013 were selected from the Netherlands Cancer Registry.
Trends in treatment and overall survival were compared
between young patients (younger than 70 years) and
elderly patients (70 years or older). Multivariable logistic
regression analysis was used to examine the probability of
patients undergoing surgery and chemotherapy in the most
recent period. Multivariable Cox regression analysis was
used to identify independent factors associated with
survival.
Results In total, 8107 young and 13,814 elderly gastric
cancer patients were included. There was a major increase
in the proportion of patients treated with resection and
chemotherapy after 2004–2008. In young patients the
increase was from 2.6% in 1999–2003 to 63% in
2009–2013 (p\ 0.01). Also an increase was noticed
among elderly patients, from 0.1% to 16% (p\ 0.01).
Median survival increased from 2004 to 2008 onward
particularly in young patients and to a lesser extent in
elderly patients (from 28 to 41 months vs from 11 to
13 months). Multivariable Cox regression analyses con-
firmed that overall survival improved for young and elderly
patients.
Discussion Young patients experienced a stronger
improvement in survival than elderly patients, resulting in
an increasing survival gap. The literature shows this is a
problem not only in the Netherlands but also throughout
Europe. The dissimilarity in treatment between young and
elderly patients could be the reason for this difference.
Keywords Stomach neoplasms  Surgery 
Chemotherapy  Epidemiology  Curative
Introduction
Gastric cancer is a disease of the elderly, with almost 60%
of all patients being older than 70 years in 2015 [1]. Since
elderly patients are often not included in clinical trials,
evidence-based guidelines are mainly based on the results
of treatment in young patients. Therefore, the best treat-
ment in the fit or frail elderly with gastric cancer and the
distinction with young patients remain unclear [2–4].
The care for elderly gastric cancer patients compared
with young patients differs in various aspects. One of the
most important differences is the large and growing
prevalence of comorbidity in elderly people; 72% of male
patients older than 80 years have comorbidity [5]. As a
result, elderly patients are considered less often to be able
to undergo a (partial) gastrectomy, even though a curative
resection offers the only chance for cure. The high
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prevalence of comorbidity also results in increasing 30-day
postoperative mortality rates, being more than 10% in
elderly gastric cancer patients (74 years or older) compared
with less than 5% for patients younger than 65 years [5, 6].
Furthermore, studies have suggested that elderly gastric
cancer patients often have a more advanced stage of dis-
ease and a larger proportion of cardia cancers, which are
associated with a poorer prognosis [7–9]. Among other
reasons, this might have led to the increasing survival
difference between older and young patients in Europe in a
previous study [10].
The outcome for gastric cancer patients remains poor,
and until recently the 5-year relative survival rate of gastric
cancer patients had not increased in any age group [11–14].
To improve survival, the treatment of gastric cancer
patients in the Netherlands has changed in recent years.
This included centralization of gastric cancer surgery with
a minimal annual volume of 20 gastrectomies, and an
increased use of (neo)adjuvant chemotherapy.
It is unclear if survival has improved through changing
management of gastric cancer in the Netherlands, and it is
not known to what extent the variation in treatment
between young and elderly patients resulted in an age-re-
lated survival difference. This study, therefore, investigates
treatment patterns and survival for young and elderly
patients with potentially curable gastric cancer in the
Netherlands.
Methods
Data were obtained from the population-based Netherlands
Cancer Registry (NCR). This registry serves the total
Dutch population of approximately 17 million inhabitants.
The NCR is based on notification of all newly diagnosed
malignancies in the Netherlands by the national automated
pathological archive (PALGA). Additional sources are the
national registry of hospital discharge and radiotherapy
institutions. Information on diagnosis, staging, and primary
treatment is routinely extracted from the medical records
by specially trained data managers of the NCR. The
information on vital status is obtained by an annual linkage
with the municipal administrative databases, which register
all deceased persons in the Netherlands and all persons
who have emigrated from the Netherlands.
Topography and morphology were coded according to
the International Classification of Diseases for Oncology,
third edition [15]. The distribution of the location in the
stomach was divided as follows: proximal/middle [fundus,
corpus, lesser and greater curvature (C16.1, C16.2, C16.5,
and C16.6)], pyloric and antrum (C16.3, C16.4), and
overlapping or not otherwise specified (C16.8, C16.9).
Tumor staging was performed according to different
versions of Union for International Cancer Control (UICC)
TNM classification, but all records were recoded to the fifth
UICC TNM classification [16]. For clinical UICC TNM
N classification, we used only N0 or N?, since the relia-
bility of evaluating the exact preoperative N category is
low [17]. To calculate tumor stage, the pathological TNM
classification was used; if this was unknown, a clinical
TNM classification was used.
For this study we selected all patients with noncardia
gastric cancer diagnosed in the period 1989–2013 who had
no clinically distant metastases (UICC TNM classification
cM0 or cMx). Tumor size was limited to tumors pene-
trating up to the serosa without invasion of adjacent
structures on clinical examination (cT0-3 or cTx according
to the fifth UICC TNM classification). These patients were
considered as potentially curable according to their clinical
TNM classification. Patients were analyzed per age group
(younger than 70 years vs 70 years or older) according to
the limits proposed by the European Society of Medical
Oncology and the Dutch clinical guidelines [5, 18].
Statistical analysis
Descriptive statistics were used to characterize the
patients the young and elderly patients. Bar graphs were
drawn to assess the variation in treatment modalities and
tumor stage throughout the years for young and elderly
patients. Univariable and multivariable logistic regression
analyses were performed for young and elderly patients to
examine the influence of different clinicopathological
factors with regard to patients undergoing surgery and
chemotherapy in the period from 2009–2013. As the
treatment paradigm for gastric cancer patients changed
over time, we decided that investigating the factors rela-
ted to treatment decisions was most interesting for recent
patients. Therefore, the logistic regression analyses were
limited to patients in whom gastric cancer had been
diagnosed in the period 2009–2013.
Survival time was defined as the time from diagnosis to
death or until February 1, 2016 for patients who were still
alive. Kaplan–Meier curves were generated to examine the
overall survival for young and elderly patients over
sequential periods. The difference in median overall sur-
vival between young and elderly patients over time was
calculated. Multivariable Cox regression analyses were
performed for young and elderly patients to investigate the
influence of various patient-, tumor-, and treatment-specific
variables on overall survival over time. The results from
survival analyses using Cox regression analyses were
reported as hazard ratios and the 95% confidence interval.
Reported p values less than 0.050 were considered statis-
tically significant. All analyses were conducted with IBM
SPSS Statistics version 23.
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Results
The number of patients with potentially curable non-
cardia gastric cancer compared with all patients with
noncardia gastric cancer is given in Table 1. In total,
21,867 patients (58%) with potentially curable noncardia
gastric cancer were selected from 38,004 patients with
noncardia gastric cancer. Not only the total number of
patients decreased but also the percentage of young
patients with potentially curable noncardia gastric cancer
decreased from 57% in 1989–1993 to 48% in
2009–2013, whereas in the elderly patients the decreased
was from 63% to 57%.
The patient and tumor characteristics of the patients
with potentially curable disease are presented in Table 2.
Compared with younger patients, elderly patients were
more often female. The tumor location of elderly patients
was more often specified as not otherwise specified or
overlapping (27% vs 32%, p\ 0.05). Young patients more
often had a diagnosis of a poorly or undifferentiated tumor
(55% vs 47%, p\ 0.05) or a signet cell carcinoma (25% vs
15%, p\ 0.05). Elderly patients more often underwent no
resection or no chemotherapy (39%) in comparison with
the young patients (10%, p\ 0.05) and as a result their
cancer was more often staged as an unknown pathological
T, N, and M category.
The proportion of young patients undergoing neither
surgery nor chemotherapy remained stable over sequential
years (9.5% vs 8.6%, p = 0.23). For elderly patients the
percentage increased significantly: between 1989 and 1993,
35% of all elderly patients did not undergo surgery or
chemotherapy, but the proportion increased to 42% in the
period 2009–2013 (p\ 0.01) (Fig. 1). In both the young
and the elderly patients there was a strong increase in the
proportion of patients treated with resection and
chemotherapy after 2004–2008; in young patients the
proportion increased from 2.6% in 1999–2003 to 63% in
2009–2013 (p\ 0.01), and in elderly patients the increase
was from 0.1% to 16% (p\ 0.01).
There were only minor differences in tumor stage dis-
tribution through the years. A shift from stage I to stage II
was seen in both young and elderly patients with gastric
cancer. Between 1989 and 1993, 40% of all young gastric
cancer patients had stage I disease and 25% had stage II
disease. Between 2009 and 2013, the proportion with stage
I disease decreased to 34% and the proportion with stage II
disease increased toward 36%. A similar trend was seen in
elderly patients (Fig. 2).
The results of the multivariable logistic regression
analyses on the chance of being treated with resection and
chemotherapy in the period 2009–2013 are presented in
Table 3. The factors that significantly influenced the
chances of patients undergoing chemotherapy and resec-
tion were mostly the same for the young and the elderly
patients. In both age groups there was a decreased chance
of patients undergoing chemotherapy and surgery with
increasing age and lower cT category (cT0/cT1 vs cT2).
Also in young patients, patients with tumors with a
favorable histological grade, overlapping or not otherwise
specified tumors, and a diagnosis in an academic hospital
had a lower chance of undergoing chemotherapy and sur-
gery. Elderly patients with a tumor of the fundus or antrum
had a significant lower chance of receiving both treatment
options.
The median overall survival over time for both age
groups of patients treated with curative intent is presented
in Fig. 3. The median survival of patients younger than
70 years increased from 30.3 months between 1989 and
1993 to 40.5 months between 2009 and 2013 (p\ 0.01).
For elderly patients, the median survival increased from
10.7 months to 13.1 months (p\ 0.01). Additionally per-
formed survival analyses on all noncardia gastric cancer
patients (i.e., patients treated with curative intent and pal-
liative intent) in the Netherlands between 1989 and 2013
showed a significant improvement of overall survival for
all gastric cancer patients from 7.6 months between 1989
and 1993 to 8.4 months between 2009 and 2013 (p\ 0.01)
(data not shown).
Patients with potentially curable gastric cancer who
underwent surgery and chemotherapy had the best 5-year
overall survival rates of 47% and 39% for the young and
elderly patients respectively (Fig. 4). Patients who did not
undergo resection or chemotherapy or who underwent only
chemotherapy had the worst survival.
Table 1 The number of all
noncardia gastric cancer
patients and the number of
patients with potentially curable
gastric cancer (cTx–3, cNx–3,
cMx–0) in the Netherlands
according to age group and
period of diagnosis
Young (\70 years) Elderly (C70 years) Total
All Curable All Curable All Curable
1989–1993 3825 2191 (57%) 5482 3467 (63%) 9307 5658 (60%)
1994–1998 3209 1758 (55%) 4881 3013 (62%) 8090 4771 (59%)
1999–2003 2916 1481 (51%) 4425 2710 (61%) 7341 4191 (57%)
2004–2008 2657 1354 (51%) 4038 2383 (59%) 6695 3737 (55%)
2009–2013 2676 1294 (48%) 3895 2216 (57%) 6571 3510 (54%)
Total 15,283 8095 (53%) 22,721 13,789 (61%) 38,004 21,867 (58%)
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Multivariable Cox regression confirmed the improved
survival over time (Table 4). In young patients survival
improved after 2004–2008, with a hazard ratio of 0.74 (95%
confidence interval 0.65–0.83) in 2009–2013 compared with
1989–1993. For the elderly patients survival improved after
1999–2003, with a hazard ratio of 0.85 (95% confidence
interval 0.80–0.90). Other factors that significantly affected
overall survival were sex, age, pathological T, N, and M
category, tumor location, morphology, and grade, treatment,
and type of diagnosing hospital, with only limited differ-
ences between young and elderly patients.
Discussion
This study is the first study to show a significantly
improved overall survival for patients with potentially
curable noncardia gastric cancer in the Netherlands in
Table 2 Patient characteristics of patients with potential curable (cTx–3, cNx–3, cMx–0) noncardia gastric cancer diagnosed between 1989 and
2013 by age
Young (\70 years),
N = 8095
Elderly (C70 years),
N = 13,789
Total,
N = 21,867
n % n % n %
Sex Male 5152 64 7733 56 12,885 59
Female 2926 36 6056 44 8982 41
pT category 0/1 1404 17 1509 11 2913 13
2 2940 36 3796 28 6736 31
3 2062 26 2393 17 4455 20
4 395 4.9 415 3.0 810 3.7
Unknown 1227 16 5676 41 6903 32
pN category 0 2592 32 3025 22 5617 26
1 2405 30 2793 20 5198 24
2 1023 13 1050 7.6 2073 9.5
3 247 3.1 250 1.8 497 2.3
Unknown 1811 22 6671 48 8482 39
pM category 0 3819 47 4651 34 8470 39
1 280 3.5 271 2.0 551 2.5
Unknown 3797 49 8867 64 12,664 58
Tumor location Proximal and middle 2621 32 3866 28 6487 30
Fundus and antrum 3260 40 5465 40 8725 40
NOS and overlapping 2214 27 4471 32 6685 31
Tumor grade Well differentiated 266 3.3 517 3.7 783 3.6
Moderately differentiated 1444 18 3263 24 4707 22
Poorly differentiated and undifferentiated 4466 55 6545 47 11,011 50
Unknown 1919 24 3477 25 5396 25
Tumor morphology Adenocarcinoma 5162 64 10,614 77 15,776 72
Nonadenocarcinoma 389 4.8 558 4.0 947 4.3
Linitis plastica 504 6.2 579 4.2 1083 5.0
Signet ring cell carcinoma 2040 25 2051 15 4091 19
Treatment group No resection, no chemotherapy 813 10 5425 39 6238 29
Resection 5698 70 7733 56 13431 61
Chemotherapy 320 4.0 174 1.3 494 2.3
Resection and chemotherapy 1264 16 470 3.4 1734 7.9
Hospital of diagnosis University 638 7.9 751 5.4 1389 6.4
Training hospital 4771 59 8186 59 12,957 59
Nontraining hospital 2669 33 4852 35 7521 34
The mean age of the young patients was 59.0 years (range 13–69 years), that of the elderly patients was 79.4 years (range 70–103 years), and
that of all patients was 71.9 years (13–103 years). For all variables, p\ 0.05
NOS not otherwise specified
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recent years. Improvement of overall survival was more
pronounced in young patients, which led to an increasing
survival difference between young and elderly patients
with potentially curable noncardia gastric cancer. Both
young and elderly patients were increasingly treated with
surgery and chemotherapy.
A lack of improvement in survival was reported in
various previous studies throughout the world. Previous
Dutch and Japanese studies did not show any improvement
of survival for stage I–III gastric cancer patients
[11, 13, 14, 19]. In the present study, median overall sur-
vival improved in potentially curable patients by 34% in
young patients and 23% in elderly patients between 1989
and 2013, which was comparable with the findings of a
large European study [20].
There could be several possible explanations for the
improvement of survival in potentially curable noncardia
gastric cancer patients. First, it might be caused by stage
migration, because patients who previously received a
diagnosis of nonmetastasized disease might nowadays
Fig. 1 Treatment modality according to period of diagnosis for young patients (left) and elderly patients (right) with potentially curable
noncardia gastric cancer
Fig. 2 Pathological tumor stage distribution by period of diagnosis for young patients (left) and elderly patients (right) with potentially curable
noncardia gastric cancer
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receive a diagnosis of metastasized disease possibly due to
the improvement of preoperative diagnostic imaging. This
would consequently lead to a group of potentially curable
patients with a better prognosis. Nevertheless, this study
showed that survival of all noncardia gastric cancer
patients (both nonmetastasized and metastasized) also
improved significantly, which indicates that stage migra-
tion cannot be the only cause for the improvement in
survival.
Another additional explanation for the improvement of
overall survival in potentially curable noncardia gastric
cancer patients could be the effect of centralization of
gastric cancer surgery in the Netherlands. Although the
beneficial effect of centralization of gastric cancer surgery
on long-term survival has not been proven so far, it is
Table 3 Multivariable logistic regression analysis on the influence of different clinicopathological factors on the probability of undergoing
surgery and chemotherapy between 2009 and 2013 for young and elderly patients with potentially curable noncardia gastric cancer
Young (\70 years) Elderly (C70 years)
OR 95% CI p OR 95% CI p
Sex Male Reference Reference
Female 0.93 0.73–1.20 0.58 0.84 0.62–1.12 0.23
Age 0.97 0.96–0.99 \0.01 0.74 0.71–0.76 \0.01
Year of diagnosis 2009 Reference Reference
2010 0.81 0.55–1.20 0.30 1.17 0.74–1.86 0.50
2011 1.09 0.73–1.62 0.68 1.29 0.82–2.03 0.27
2012 1.01 0.69–1.49 0.94 1.22 0.77–1.94 0.40
2013 0.98 0.66–1.46 0.94 1.33 0.84–2.11 0.22
cT category 0/1 0.18 0.10–0.32 \0.01 0.32 0.16–0.65 \0.01
2 Reference Reference
3 0.67 0.36–1.26 0.22 1.10 0.50–2.42 0.81
Unknown 0.64 0.49–0.84 \0.01 0.60 0.45–0.81 \0.01
cN category 0 Reference Reference
cN1–3 1.08 0.82–1.44 0.58 1.14 0.83–1.58 0.41
Unknown 0.54 0.38–0.77 \0.01 0.43 0.27–0.68 \0.01
Tumor morphology Adenocarcinoma Reference Reference
Nonadenocarcinoma 1.13 0.73–1.73 0.58 0.87 0.51–1.49 0.61
Linitis plastica 0.92 0.56–1.53 0.76 0.71 0.37–1.35 0.30
Signet ring cell carcinoma 1.06 0.78–1.44 0.69 1.16 0.81–1.65 0.42
Tumor grade Well differentiated 0.30 0.11–0.82 0.02 0.46 0.15–1.45 0.19
Moderately differentiated 0.56 0.38–0.84 0.01 0.66 0.44–1.01 0.06
Poorly differentiated and undifferentiated Reference Reference
Unknown 1.01 0.78–1.31 0.96 1.15 0.85–1.56 0.36
Tumor location Proximal and middle Reference Reference
Fundus and antrum 0.89 0.67–1.18 0.42 0.57 0.41–0.79 \0.01
NOS and overlapping 0.60 0.43–0.85 \0.01 0.79 0.55–1.12 0.18
Diagnosing hospital University 0.40 0.26–0.62 \0.01 0.60 0.33–1.07 0.08
Training hospital Reference Reference
Nontraining hospital 1.16 0.89–1.51 0.27 1.12 0.83–1.50 0.46
Values in italic are statistically significant
CI confidence interval, NOS not otherwise specified, OR odds ratio
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Fig. 3 Median survival per period of diagnosis for patients with
potentially curable noncardia gastric cancer and the difference
between both age groups
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thought to improve outcome after gastrectomy [21, 22].
From 2012 gastrectomies in the Netherlands were cen-
tralized to a minimum of ten per hospital per year, and as of
2013 this has been increased to a minimum of 20 per year.
In this study, overall survival already started to improve
before 2012, indicating that the introduction of the minimal
annual volume norm is also not the only cause for
improvement of survival but it could partly explain the
survival improvement in recent years.
The Magic trial reported better survival rates for patients
who underwent perioperative chemotherapy and surgery
compared with surgery alone for gastric cancer. Since 2006
chemotherapy has been increasingly used in the Nether-
lands [13, 23]. Since then two meta-analyses on the effect
of adjuvant and neoadjuvant chemotherapy on overall and
disease-free survival have demonstrated a positive effect
on survival [24, 25]. In the present study a strong increase
in the use of chemotherapy was observed in the Nether-
lands, in particular in young patients. This increased use of
perioperative chemotherapy might be an important factor
in the improved survival demonstrated in recent years.
Apart from increased overall survival in young and
elderly patients, the present study showed an increasing
survival gap between young and elderly patients. When
these results are put into a European perspective, a similar
result was observed in a large number of population-based
cancer registries throughout Europe [10, 26, 27]. The
EUROCARE IV and EUROCARE V studies as well as the
EUROCARE study on age-related survival differences
showed not only a significantly improved overall survival
but also an increased survival difference between young
and elderly patients [10, 26, 27].
The present study, which was done later than the
EUROCARE studies, observed an even greater increase in
the overall survival difference between young and elderly
patients compared with the EUROCARE studies, espe-
cially in recent years. Among other reasons, this might be
caused by differences in treatment between young and
elderly patients. Noticeable is the proportion of patients
who did not undergo surgery or chemotherapy. In young
patients, the proportion of patients has remained stable at
around 10% in the last 20 years. For elderly patients, the
proportion has increased significantly from 35% to 42% in
the same period. An explanation for this increasing per-
centage might be the better understanding of age-related
differences in treating gastric cancer. Many studies have
reported potential risks of surgery and/or chemotherapy in
elderly patients, which could have stopped clinicians from
treating patients older than 70 years [28, 29].
On the other hand, the percentage of patients undergoing
both surgery and chemotherapy increased in both age
groups, but to a much lesser extent in elderly patients.
Patients treated with both chemotherapy and resection have
the highest survival rate in the present study. However,
there most likely is a selection bias, as fitter patients are
likelier to be treated more extensively.
It remains unclear whether omitting any form of treat-
ment is caused by good clinical judgment or is because of
the clinicians’ assumption that chronological age makes
elderly patients unfit for therapy [10]. Previous studies
based on data from the NCR showed a large variation in the
probability of patients undergoing surgery, ranging from
53% to 83% according to hospital diagnoses between 2005
and 2013 [12, 30]. This suggests that the treatment regimen
Fig. 4 Kaplan–Meier 5-year overall survival curve per treatment method for young patients (left) and elderly patients (right) with potentially
curable noncardia gastric cancer
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is determined not only by patient- and/or disease-specific
factors. This variation significantly impacted survival [30].
Furthermore, the chance of receiving (neo)adjuvant treat-
ment also varied between regions. Depending on the region
of treatment, the odds ratio of receiving (neo)adjuvant
treatment ranged from 0.7 to 4.5 [12].
The limitations of this study are the lack of data on
comorbidity, performance status, and the possible
Table 4 Cox regression analyses on the influence of different clinicopathological factors on overall survival in young and elderly patients with
potentially curable noncardia gastric cancer
Young (\70 years) Elderly (C70 years)
HR 95% CI p HR 95% CI p
Sex Male Reference Reference
Female 0.92 0.88–0.98 \0.01 0.83 0.80–0.86 \0.01
Age 1.03 1.02–1.03 \0.01 1.03 1.02–1.03 \0.01
Period of diagnosis 1989–1993 Reference Reference
1994–1998 1.01 0.94–1.08 0.82 1.01 0.96–1.06 0.69
1999–2003 0.97 0.90–1.05 0.46 0.90 0.85–0.95 \0.01
2004–2008 0.90 0.83–0.99 0.02 0.85 0.80–0.90 \0.01
2009–2013 0.74 0.65–0.83 \0.01 0.72 0.67–0.76 \0.01
pT category 0/1 0.36 0.33–0.40 \0.01 0.56 0.51–0.60 \0.01
2 Reference Reference
3 0.72 0.67–0.77 \0.01 0.78 0.73–0.82 \0.01
4 1.32 1.17–1.49 \0.01 1.35 1.20–1.51 \0.01
Unknown 1.14 0.97–1.33 0.11 1.32 1.17–1.50 \0.01
pN category 0 Reference Reference
1 1.74 1.62–1.86 \0.01 1.54 1.46–1.64 \0.01
2 2.28 2.09–2.49 \0.01 2.09 1.94–2.26 \0.01
3 2.98 2.54–3.49 \0.01 2.42 2.09–2.80 \0.01
Unknown 1.08 0.96–1.21 0.21 1.18 1.09–1.27 \0.01
pM category 0 Reference Reference
1 1.92 1.69–2.18 \0.01 1.83 1.61–2.07 \0.01
Unknown 0.96 0.90–1.02 0.16 1.05 1.00–1.10 0.05
Tumor location Proximal and middle Reference Reference
Fundus and antrum 1.09 1.03–1.16 0.01 1.04 1.00–1.09 0.05
NOS and overlapping 1.26 1.18–1.35 \0.01 1.23 1.17–1.28 \0.01
Tumor morphology Adenocarcinoma Reference Reference
Nonadenocarcinoma 1.25 1.10–1.41 \0.01 1.20 1.09–1.31 \0.01
Linitis plastica 1.79 1.61–1.99 \0.01 1.47 1.34–1.60 \0.01
Signet ring cell carcinoma 1.07 1.00–1.14 0.05 1.11 1.05–1-16 \0.01
Tumor grade Well differentiated 1.03 0.90–1.20 0.65 0.84 0.76–0.92 \0.01
Moderately differentiated 0.90 0.84–0.97 \0.01 0.90 0.86–0.94 \0.01
Poorly differentiated and undifferentiated Reference Reference
Unknown 0.94 0.88–1.01 0.08 0.86 0.82–0.90 \0.01
Treatment No resection, no chemotherapy Reference Reference
Resection 0.25 0.21–0.30 \0.01 0.42 0.37–0.48 \0.01
Chemotherapy 0.92 0.80–1.05 0.21 0.99 0.85–1.16 0.93
Resection and chemotherapy 0.20 0.17–0.25 \0.01 0.30 0.25–0.36 \0.01
Diagnosing hospital University 0.79 0.71–0.88 \0.01 0.84 0.77–0.91 \0.01
Training hospital Reference Reference
Nontraining hospital 0.97 0.92–1.02 0.26 1.03 1.00–1.07 0.08
Values in italic are statistically significant
CI confidence interval, HR hazard ratio, NOS not otherwise specified
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contributing reasons to forgo surgery or chemotherapy.
These factors are known to impact treatment choice and
survival. We were, however, unable to adjust the data for
these factors in our analyses since these factors are not
routinely collected by the NCR on a national level. The
main strength of the study is the size of the study popu-
lation and the fact that the study is based on nationwide
population-based data, which makes it possible to investi-
gate trends in treatment, survival, and the influence of
various clinicopathological factors on treatment and sur-
vival, representing daily clinical practice.
In conclusion, overall survival of potentially curable
noncardia gastric cancer patients has significantly
improved in recent years. Especially young patients
showed a strong improvement of survival, a trend that is
seen throughout Europe [26, 27]. This strong improvement
of overall survival could be caused by a higher proportion
of patients undergoing both surgery and chemotherapy.
Besides, further research will be needed to improve sur-
vival in (frail) elderly gastric cancer patients to prevent a
further increase in the survival gap between young and
elderly gastric cancer patients.
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